ProQR Therapeutics (PRQR) Invested Capital (2013 - 2025)

ProQR Therapeutics' Invested Capital history runs 13 years deep, the most recent figure standing at $70.4 million for Q4 2025.

• In Q4 2025, Invested Capital fell 34.91% year-over-year to $70.4 million; the TTM figure through Dec 2025 stood at $70.4 million (down 34.91% YoY), while the FY2025 annual figure was $70.4 million, down 34.91% from the prior year.
• Invested Capital came in at $70.4 million for Q4 2025 at ProQR Therapeutics, down from $108.1 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $175.8 million in Q4 2021 to a low of $79903.5 in Q1 2021.
• A 5-year average of $98.2 million and a median of $77.0 million in 2022 frame the typical range for Invested Capital.
• Across the five-year window, Invested Capital slumped 99.92% in 2021 and soared 195418.42% in 2022, its largest moves.
• ProQR Therapeutics' Invested Capital stood at $175.8 million in 2021, then sank by 52.47% to $83.5 million in 2022, then dropped by 26.8% to $61.1 million in 2023, then surged by 76.84% to $108.1 million in 2024, then sank by 34.91% to $70.4 million in 2025.
• According to Business Quant data, Invested Capital over the past three periods registered $70.4 million, $108.1 million, and $61.1 million for Q4 2025, Q4 2024, and Q4 2023 respectively.

Peer Comparison